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INTRODUCTION 
 
        
          AIDS was first recognized in the United States in the summer of 
1981, when the U.S. Centers for Disease Control and Prevention (CDC) 
reported the unexplained occurrence of Pneumocystis jiroveci and 
Kaposi's sarcoma (KS) previously healthy homosexual men[1]. By 1984, it 
became apparent that there was a renal syndrome associated  with HIV  
infection that  was characterized  by severe proteinuria and rapidly 
progressive renal failure[2].   
          HIV infection is a global pandemic, with cases reported from 
virtually every country. At the end of 2009, an estimated 33.3 million 
individuals were living with HIV infection according to the Joint United 
Nations Programme on HIV/AIDS (UNAIDS). More than 95% of people 
living with HIV/AIDS reside in low- and middle-income countries. The 
global prevalence has increased approximately fourfold since 1990, 
reflecting the combined effects of continued high rates of new HIV 
infections and the beneficial (life-prolonging) impact of antiretroviral 
therapy[1].  
          The introduction of combination antiretroviral therapy (cART) in 
the treatment of human immunodeficiency virus (HIV) infection has led 
to a substantial decline in HIV-related mortality and morbidity [3,4]. 
However, it has also resulted in important short- and long-term adverse 
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effects [5]. Recent data indicate that the rate of cardiovascular disease is 
increased in patients with HIV infection on combination antiretroviral 
therapy, although the role of antiretroviral therapy and abnormalities of 
body composition is debated [6,7].                   
         Microalbuminuria is a marker of renal damage that is associated 
with increased risk of cardiovascular disease(CVD) and mortality in the 
general population [8–11]. The pathophysiological mechanism underlying 
urinary albumin excretion and the increased risk of CVD is not fully 
understood, although systemic endothelial dysfunction and inflammation 
have been implicated [12,13]. There is also some evidence that 
microalbuminuria might represent an early indicator of HIVAN [14]. Thus, 
early detection of microalbuminuria could identify HIV-infected subjects 
at high risk of developing CVD and even renal diseases. 
           The objective of the study was to evaluate if HIV infection was an 
independent risk factor for microalbuminuria and second, to identify 
significant predictors of microalbuminuria in HIV-infected individuals. 
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AIMS AND OBJECTIVES 
 
1). To estimate the prevalence of microalbuminuria in HIV infected 
individuals. 
 
2).  To analyse the association of Duration of HIV infection, CD4 count, 
Serum Creatinine, Blood pressure, Glomerular Filtration Rate and cART 
intake independently with microalbuminuria. 
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REVIEW OF LITERATURE 
Since the recognition of Acquired immunodeficiency syndrome (AIDS) 
in 1981, in 1983, the causative retrovirus was isolated and subsequently 
named human immunodeficiency virus (HIV). In 1986, a second 
retrovirus causing AIDS, HIV-2, was identified in West Africa. It 
remains largely confined to this region, while HIV-1 is the cause of the 
world pandemic of AIDS[15].  
EPIDEMIOLOGY 
GLOBAL CONSIDERATIONS 
Since the beginning of the epidemic, almost 60 million people have been 
infected with HIV and 25 million people have died of HIV-related causes. 
The Global estimates for adults and children for 2009 indicates there are 
an estimated 33.3 million people living with HIV out of which 2.6 million 
are new HIV infections. AIDS accounted for 1.8 million deaths in the 
same  year.  Over  7000  new  HIV  infections  occur  in  a  day  of  which 
about 97% are in low and middle income countries. Among the infected 
about 1000 are children under 15 years of age, about 6000 are in adults 
aged 15 years and older, of whom 51% are women and 41% are among 
young people (15-24years) [16]. 
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INDIAN SCENARIO 
Asia is second only to sub-Saharan Africa in terms of people living with 
HIV. India accounts for roughly half of Asia’s HIV prevalence[16]. The 
epidemic in India shows a declining trend overall.  HIV prevalence 
among adult population in 2007 was 0.34 percent and in 2008 was 0.29 
percent.  There is also a declining number of PLHIV in the country, with 
an estimated 2.27 million PLHIV in 2008 compared to 2.31 million in 
2007. While there is a decline in the epidemic among FSW in south 
Indian states, rising trends are evident in the North East where the 
epidemic is increasingly driven both by IDU and sexual transmission[17].     
 
ETIOLOGICAL AGENT[1,15] 
HIV belongs to the family of human retroviruses (Retroviridae) and the 
subfamily of lentiviruses .The most common cause of HIV disease 
throughout the world is HIV-1, which comprises 11 sequence subtypes 
(or clades), A to K, of the main group M, and N (new) and O (outlier).  
HIV-2 too is subdivided into groups A through G each are likely derived 
from a separate transfer to humans from a nonhuman primate reservoir. 
The AIDS pandemic is primarily caused by the HIV-1 M group viruses 
whereas HIV-1 group O and HIV-2 viruses have caused much more 
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localized epidemics. The predominant clade of virus in southern Africa as 
well as India is Clade C.  
 
HIV GENOME[15] 
 
 
 
HIV has only nine genes. The three structural genes are gag, pol, and env, 
encoding the core proteins (p17, p24, and p15), the enzymes (protease, 
reverse transcriptase, and integrase), and the envelope glycoproteins 
(gp120 and gp41), respectively. The major regulatory genes tat and rev 
encode proteins that are essential for replication in the cell. The Tat 
 7 
protein acts in positive feedback to enhance transcription, while the Rev 
protein helps the efficient transport of viral RNA from the nucleus to the 
cytoplasm. The functions of the four accessory genes Vif  Nef  Vpu Vpr 
of HIV are less well understood. Unlike HIV-1, HIV-2 and the simian 
immunodeficiency viruses (SIV) lack vpu, but have an alternative gene, 
vpx. 
PATHOGENESIS[1,15] 
The outer envelope glycoprotein, gp120  binds to CD4 and subsequently 
to the coreceptor. Gp120 is anchored to the viral envelope via gp41, the 
viral protein that is thought to effect membrane fusion. HIV uses two 
major co-receptors, CCR5 and CXCR4, for fusion and entry. The 
mechanisms responsible for cellular depletion and  immune dysfunction 
of CD4+ T cells include direct infection and destruction of these cells by 
HIV, as well as indirect effects such as immune clearance of infected 
cells, immune exhaustion due to aberrant cellular activation, and 
activation-induced cell death. Patients with CD4+ T cell levels below 
certain thresholds are at high risk of developing a variety of opportunistic 
diseases, particularly the infections and neoplasms that are AIDS-
defining illnesses. High levels of MIP-1α or -β in the blood, 
homozygosity for an inherited defect of the CCR5 receptor involving a  
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32 bp deletion in the CCR5 gene and the Duffy antigen receptor for 
chemokines (DARC) correlate with relative resistance to HIV infection. 
DIAGNOSIS[1] 
The standard blood screening test for HIV infection is the ELISA, also 
referred to as an enzyme immunoassay (EIA). This solid-phase assay is 
an extremely good screening test with a sensitivity of >99.5%. The most 
commonly used confirmatory test is the Western blot  . A Western blot 
demonstrating antibodies to products of all three of the major genes of 
HIV (gag, pol, and env) is conclusive evidence of infection with HIV. In 
case of an indeterminate Western blot, one may attempt to confirm a 
diagnosis of HIV infection with the p24 antigen capture assay or one of 
the tests for HIV RNA such as reverse transcriptase PCR (RT-PCR), 
branched DNA (bDNA), and nucleic acid sequence–based amplification 
(NASBA). 
CLINICAL STAGING[18] 
WHO clinical staging of HIV disease in adults and adolescents 
Clinical stage 1 
 Asymptomatic  
 Persistent generalized lymphadenopathy 
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Clinical stage 2 
 Moderate unexplained weight loss (under 10% of presumed or 
measured body weight) 
 Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis 
media, pharyngitis)  
 Herpes zoster  
 Angular cheilitis 
 Recurrent oral ulcerations  
 Papular pruritic eruptions 
 Seborrhoeic dermatitis  
 Fungal nail infections  
Clinical stage 3  
 Unexplained severe weight loss (over 10% of presumed or 
measured body weight)  
 Unexplained chronic diarrhoea for longer than 1 month 
 Unexplained persistent fever (intermittent or constant for longer 
than 1 month)  
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 Persistent oral candidiasis  
 Oral hairy leukoplakia  
 Pulmonary tuberculosis 
 Severe bacterial infections (e.g. pneumonia, empyema, meningitis, 
pyomyositis, bone or joint infection, bacteraemia, severe pelvic 
inflammatory disease) 
 Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
 Unexplained anaemia (below 8 g/dl ), neutropenia (below 0.5 x 
109/l) and/or chronic thrombocytopenia (below 50 x 109/l) 
Clinical stage 4 
 HIV wasting syndrome  
 Pneumocystis jiroveci pneumonia  
 Recurrent severe bacterial pneumonia  
 Chronic herpes simplex infection (orolabial, genital or anorectal of 
more than 1 month’s duration or visceral at any site) 
 Oesophageal candidiasis (or candidiasis of trachea, bronchi or 
lungs) 
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 Extrapulmonary tuberculosis  
 Kaposi sarcoma 
 Cytomegalovirus disease (retinitis or infection of other organs, 
excluding liver, spleen and lymph nodes) 
 Central nervous system toxoplasmosis 
 HIV encephalopathy 
 Extrapulmonary cryptococcosis including meningitis 
 Disseminated nontuberculous mycobacteria infection  
 Progressive multifocal leukoencephalopathy  
 Chronic cryptosporidiosis 
 Chronic isosporiasis  
 Disseminated mycosis (histoplasmosis, coccidiomycosis)  
 Recurrent septicaemia (including nontyphoidal Salmonella) 
 Lymphoma (cerebral or B cell non-Hodgkin) 
 Invasive cervical carcinoma  
 Atypical disseminated leishmaniasis 
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 Symptomatic HIV-associated nephropathy or HIV-associated 
cardiomyopathy 
AIDS CASE DEFINITION[19] 
CDC AIDS case definition for surveillance of adults and adolescents 
Definitive AIDS diagnoses (with or without laboratory evidence of 
HIV infection)  
 Candidiasis of the esophagus, trachea, bronchi, or lungs. 
 Cryptococcosis, extrapulmonary. 
 Cryptosporidiosis with diarrhea persisting > 1 month. 
 Cytomegalovirus disease of an organ other than liver, spleen, or 
lymph nodes. 
 Herpes simplex virus infection causing a mucocutaneous ulcer 
that persists longer than 1 month; or bronchitis, pneumonitis, or 
esophagitis of any duration. 
 Kaposi sarcoma in a patient < 60 years of age. 
 Lymphoma of the brain (primary) in a patient < 60 years of age. 
 Mycobacterium avium complex or Mycobacterium kansasii 
disease, disseminated  
 Pneumocystis jiroveci pneumonia.  
 Progressive multifocal leukoencephalopathy. 
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 Toxoplasmosis of the brain. 
 
Definitive AIDS diagnoses (with laboratory evidence of HIV 
infection)  
 Coccidioidomycosis, disseminated  
 HIV encephalopathy. 
 Histoplasmosis, disseminated  
 Isosporiasis with diarrhea persisting > 1 month. 
 Kaposi sarcoma at any age. 
 Lymphoma of the brain (primary) at any age. 
 Other non-Hodgkin lymphoma of B cell or unknown immunologic 
phenotype. 
 Disseminated non tuberculous mycobacterial disease  
 Disease caused by extrapulmonary M tuberculosis.  
 Salmonella (nontyphoid) septicemia, recurrent.  
 HIV wasting syndrome. 
 CD4 lymphocyte count below 200 cells/mcL or a CD4 lymphocyte 
percentage below 14%. 
 Pulmonary tuberculosis. 
 Recurrent pneumonia. 
 Invasive cervical cancer. 
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Presumptive AIDS diagnoses (with laboratory evidence of HIV 
infection)  
 Candidiasis of esophagus 
 Cytomegalovirus retinitis 
 Mycobacteriosis 
 Kaposi sarcoma 
 Pneumocystis jiroveci pneumonia 
 Toxoplasmosis of the brain 
 Recurrent pneumonia 
 Pulmonary Tuberculosis  
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Criteria for ART Initiation in specific populations[20] 
 
Target population Clinical condition Recommendation 
 
Asymptomatic 
individuals  
(including pregnant  
women) 
 
WHO clinical stage 1 Start ART if CD4 
≤350 
 
WHO clinical stage 2 Start ART if CD4 
≤350 
 
Symptomatic 
individuals (including 
pregnant  
women) 
 
WHO clinical stage 3 
or 4 
 
Start ART irrespective 
of  
CD4 cell count 
 
Active TB disease 
 
Start ART irrespective 
of  
CD4 cell count 
 
TB and hepatitis B  
coinfections 
HBV infection 
requiring  
treatment* 
Start ART irrespective 
of  
CD4 cell count 
  
*The current standard definition of chronic active hepatitis is mainly 
based on histological parameters obtained by liver biopsy. 
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Preferred first-line ART in treatment-naive adults and adolescents[20] 
 
 
Target population Preferred options* 
Adults and adolescents 
 
AZT or TDF + 3TC or  
FTC + EFV or NVP 
 
Pregnant women** 
 
AZT + 3TC + EFV or  
NVP 
 
HIV/TB coinfection*** AZT or TDF + 3TC or  
FTC + EFV 
 
HIV/HBV coinfection**** 
 
TDF + 3TC or FTC +  
EFV or NVP 
 
 
 
 
* Use fixed-dose combinations  
** Do not initiate EFV during first trimester 
*** Initiate ART as soon as possible (within the first 8 weeks) after 
starting TB treatment 
**** Use of two ARVs with anti-HBV activity required 
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ANTIRETROVIRAL REGIMEN FOR ANTIRETROVIRAL 
NAIVE PATIENTS[21] 
 
Preferred Regimens (Regimens with optimal and durable efficacy, 
favourable tolerability and toxicity profile, and ease of use) 
 NNRTI-Based Regimen  
          EFV/TDF/FTC   
 PI-Based Regimens  
          ATV/r + TDF/FTC   
          DRV/r (once daily) + TDF/FTC   
 INSTI-Based Regimen  
          RAL + TDF/FTC   
 Preferred Regimen for Pregnant Women 
          LPV/r (twice daily) + ZDV/3TC  
Alternative Regimens (Regimens that are effective and tolerable but 
have potential disadvantages compared with preferred regimens) 
 NNRTI-Based Regimens  
          EFV + ABC/3TC  
          RPV/TDF/FTC   
          RPV + ABC/3TC  
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 PI-Based Regimens  
          ATV/r + ABC/3TC   
          DRV/r + ABC/3TC   
          FPV/r (once or twice daily) + ABC/3TC1or TDF/FTC   
          LPV/r (once or twice daily) + ABC/3TC1or TDF/FTC   
 INSTI-Based Regimen  
          RAL + ABC/3TC   
 
Acceptable Regimens (Regimens that may be selected for some patients 
but are less satisfactory than preferred or alternative regimens) 
 NNRTI-Based Regimen  
          EFV + ZDV/3TC   
          NVP + (TDF/FTC1or ZDV/3TC)   
          NVP + ABC/3TC   
          RPV + ZDV/3TC   
 PI-Based Regimens  
          ATV + (ABC or ZDV)/3TC   
          ATV/r + ZDV/3TC   
          DRV/r + ZDV/3TC   
          FPV/r + ZDV/3TC   
          LPV/r + ZDV/3TC  
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 INSTI-Based Regimen  
          RAL + ZDV/3TC   
 CCR5 Antagonist-Based Regimens  
          MVC + ZDV/3TC   
          MVC + TDF/FTC1or ABC/3TC  
Regimens that may be acceptable but should be used with caution 
 PI-Based Regimens  
          SQV/r + TDF/FTC   
          SQV/r + (ABC or ZDV)/3TC   
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ART SWITCHING CRITERIA[20] 
 
Failure Definition 
Clinical failure* 
 
New or recurrent WHO  
stage 4 condition 
 
Immunological failure** 
 
Fall of CD4 count to baseline  (or 
below) OR 
50% fall from on-treatment peak 
value OR 
Persistent CD4 levels below 100 
cells/mm3 
 
Virological failure*** 
 
Plasma viral load above  
5000 copies/ml 
 
* Condition   must    be    differentiated     from   immune   reconstitution 
inflammatory syndrome (IRIS). Certain WHO clinical stage 3 conditions 
(e.g. pulmonary TB, severe bacterial infections), may be an indication of 
treatment failure. 
** Without  concomitant  infection  to  cause  transient CD4 cell decrease  
*** The optimal viral load threshold for defining virological failure has 
not been determined.  
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RENAL MANIFESTATIONS OF HIV 
A causal relationship between infection and nephropathy was initially 
established by epidemiological studies in which epidemic or endemic 
infections were associated with specific glomerular abnormalities which 
resolves following effective treatment of the underlying infection. Viral 
infection may produce glomerular effects by three different mechanisms: 
a direct cytopathic effect of the virus on glomerular cells, stimulation of 
an antibody response resulting in immune complex formation, and a 
direct effect on T cells altering the helper-to-suppressor ratio and 
affecting humoral immunity. The HIV is associated with a focal 
segmental glomerulosclerosis (FSGS), but the case reports include large 
numbers of intravenous drug abusers and patients with opportunistic 
infections, and a direct causal relationship is difficult to establish.[22]  
The renal manifestations of HIV can be classified as 
 
GLOMERULAR LESIONS 
HIV-associated FSGS and related mesangiopathies (HIVAN) 
Immune-complex-mediated glomerular diseases  
 MPGN 
 IgA nephropathy  
 Lupus-like Glomerulonephritis 
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 Haemolytic uraemic syndrome/ thrombotic thrombocytopaenic 
purpura[23,24]  
 
TUBULOINTESTITIAL LESIONS  
Acute tubular necrosis  
Interstitial nephritis  
Drug-related interstitial nephritis 
Neoplasms including lymphoma and Kaposi's sarcoma  
 
RENAL INFECTIONS 
Pyelonephritis 
Opportunistic infections such as aspergillosis , Pseudallescheria boydii, 
murcomycosis, adenoviruses[25,26,27,28]  
 
CLASSIC HIVAN 
Classic HIVAN is the most commonly reported chronic renal disease 
associated with HIV infection. [29,30,31,32,33] It is the third leading cause of 
ESRD among African Americans aged 20 to 64, following only diabetes 
and hypertension.[34,35]  There is a strong predilection for HIVAN among 
HIV-infected patients of African Heritage.[36] Intravenous drug use has 
been the most common risk factor for the HIVAN, though it has been 
seen in all groups at risk for AIDS including homosexuals, perinatally 
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acquired disease, heterosexual transmission, and exposure to 
contaminated blood products.[33] HIVAN usually occurs in patients with a 
low CD4 count. The onset of HIVAN was most common in otherwise 
asymptomatic HIV-infected patients.[37,38] There is no relationship 
between the development of HIVAN and patient age and duration of HIV 
infection, or types of opportunistic infections or malignancies.[33]  
 
PATHOGENESIS 
 
HIV-1 RNA was detected in renal tubular epithelial cells, glomerular 
epithelial cells (visceral and parietal), and interstitial leukocytes 
supporting a role for direct HIV-1 infection of renal parenchymal cells.[39] 
The nef gene induces podocyte proliferation and differentiation that are 
characteristic of HIVAN. Vpr has been demonstrated to induce cell cycle 
arrest  in the G2 phase and play a role in nuclear  import of the HIV 
preintegration complex, transactivation of the viral  long terminal  repeat 
(LTR) promoter, and apoptosis.[40] Host genes also play a role in the 
pathogenesis of HIVAN. The expression of two cyclin-dependent kinase 
inhibitors p27 and p57, were decreased in podocytes from HIVAN 
biopsies whereas expression of CDK inhibitor, p21, was increased.[41] 
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PATHOLOGY 
 
HIVAN has been termed a “pan nephropathy” because of characteristic 
involvement of the glomeruli, tubules, and interstitium[42]. FSGS is the 
most common lesion in adults with podocyte proliferation and loss of 
differentiation markers, often coexisting with glomerular collapses and 
tubular pathology including atrophy and microcystic dilations[22]. The 
interstitium shows infiltration by leucocytes, primarily CD8+ T-
lymphocytes and macrophages. Interstitial oedema and fibrosis is 
frequently noted. Mesangial hyperplasia is considered as an early stage of 
FSGS[30]. Though focal glomerulosclerosis are not specific, the 
concomitant findings of glomerular collapse, glomerular and tubular 
epithelial cell abnormalities, increased mesangial matrix, renal tubular 
atrophy or microcystic dilation, and interstitial immune cell infiltration, in 
combination with tubular reticular structures are virtually diagnostic of 
classic HIVAN[22,29,42]. 
         On electron microscopy, there  is almost complete effacement of 
podocyte foot processes and the visceral epithelial cytoplasm can have  
large, electron-dense  resorption droplets. The endothelium  has  large  
tubuloreticular inclusions located within the cisternae of the endoplasmic 
reticulum or the Golgi bodies[43,44,45].  
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CLINICAL FEATURES 
The clinical features of HIVAN include presenting features of 
proteinuria, typically in the nephrotic range, and renal insufficiency. 
Other manifestation of the nephrotic syndrome including edema, 
hypoalbuminemia, hypercholesterolemia and hypertension have been less 
common even in patients with severe renal failure.[37,38,43,46,47,48,49] Some 
patients present with subnephrotic range proteinuria, and urinary 
sediment findings of microhematuria and sterile pyuria.[50]The renal 
ultrasound in HIVAN show echogenic kidneys with preserved or 
enlarged size with an average of over 12 cm in spite of the severe renal 
insufficiency.[38,47] Microcystic dilation is responsible for increased 
kidney echogenicity and size. Echogenicity may correlate with the 
histopathologic tubulo-interstitial changes better than the glomerular 
changes.[51]  
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TREATMENT 
HAART 
The first reports of HIVAN regression was in response to zidovudine 
therapy [52,53] . The use of HAART appeared to be superior to nucleoside 
analog treatment alone, and appeared to account for the decreased 
incidence of HIVAN diagnosis. Multivariate analysis demonstrated a 
significantly lower progression of disease with ART[54]. Cessation of 
treatment may not be safe once a diagnosis of HIVAN  is made and  if 
antiretroviral medications must be withheld, patients should be monitored 
for worsening renal function or proteinuria[55]. There are reports of 
patients with dialysis-dependent renal failure sucessfully treated with 
HAART and repeat renal biopsies in both patients revealing resolution of 
the histological lesions including collapsing FSGS and tubular 
microcystic dilation [56,57].  
ACE INHIBITORS 
Administration of captopril to HIV-transgenic mice that exhibited 
characteristics of HIVAN was associated with improvement of urinary 
protein excretion, azotemia, and histologic abnormalities[58]. ACE 
inhibitors have been shown  to enhance renal survival, stabilize serum 
creatinine and decrease proteinuria in HIVAN and to slow the 
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progression to renal failure[59,60,61,62,63]. Serum ACE levels are elevated in 
HIV patients  and   ACE   inhibitors   may   prevent   proteinuria  and 
glomerulosclerosis by hemodynamic mechanisms, modulation of matrix 
production and mesangial cell proliferation, affecting HIV protease 
activity and by decreasing the expression of transforming growth factor 
beta[58,59,61,62,63,64,65]. 
CORTICOSTEROIDS 
Tubulointerstitial inflammation is one of the most prominent 
histopathologic findings  in HIVAN and the  inflammatory response of  
renal parenchymal cells to HIV  infection  is an important component of 
HIVAN pathogenesis. . A beneficial effect of steroid treatment upon 
tubulointerstitial inflammation has been suggested[66]. Glucocorticoids 
has been found to be effective in slowing the progression of HIVAN, 
diminution in urinary protein excretion and improvement in renal 
function[29,59,65,67,68,69,70]. But there was a relatively high frequency of side 
effects such as psychosis, gastrointestinal bleeding, and infections [70]. 
Remissions in HIV-infected children with the minimal change pattern on 
biopsy treated with steroids have been noted, but not in children with 
sclerosing or collapsing lesions[33].  
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IMMUNOSUPPRESSANTS 
Limited data suggested cyclosporine ameliorated the course of the renal 
disease , but only few patients have been assessed and concern has been 
raised regarding the risk/benefit ratio of immunosuppression in patients 
with HIV infection[65]. 
RENAL REPLACEMENT THERAPY 
Early reports indicated that survival on dialysis was limited and that 
peritoneal dialysis seemed to be preferable. The course of therapy for 
dialysis patients is improving, but depends on the stage of the viral 
illness[21].The current consensus is that renal transplantation is no longer a 
contraindication in HIV-positive patients, and outcomes have improved 
in HIVAN patients who received renal transplants[71,72] and the British 
HIV Association have published guidelines on this topic[73]. 
RENAL DISEASES RELATED TO TREATMENT 
Drugs commonly associated with renal damage in patients with HIV 
disease are pentamidine, amphotericin, adefovir, cidofovir, tenofovir, and 
foscarnet. Cotrimoxazole may compete for tubular secretion with 
creatinine and cause an increase in the serum creatinine level. 
Sulfadiazine may crystallize in the kidney and result in an easily 
reversible form of renal shutdown[1]. Indinavir and ritonavir , can cause 
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reversible nephropathy[65,74,75]. Glomerulonephritis in HIV-infected 
patients may be secondary to a host response to treatment with Interferon 
alpha[76]. 
MICROALBUMINURIA 
Microalbuminuria refers to elevated urine albumin excretion that is below 
the level of detection by routine urine protein dipstick test. 
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CLASSIFICATION OF ABNORMAL URINE ALBUMIN [77] 
Spot Urine 
Albumin 
(mg/L) 
Albumin/Creatinine 
Ratio 
 24-H Urine 
Albumin 
(mg/24 h) 
Overnight 
Urine 
Albumin 
(µg/24 h) 
 Gen
der 
mg/ 
mmol 
mg/g 
Normal <15 <10 <10 M <1.25 <10 
    F <1.75 <15 
High 
Normal 
15 to <30 10 to <20 10 to 
<20 
M 1.25 to 
<2.5 
10 to 
<20 
    F 1.75 to 
<3.5 
15 to 
<30 
Micro 
albumin 
uria 
30 to <300 20 to <200 20 to 
<200 
M 2.5 to 
<25 
20 to 
<200 
    F 3.5 to 
<35 
30 to 
<300 
Macro 
albumin 
uria 
>300 >200 >200 M >25 >200 
    F >35 >300 
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Albumin excretion and microalbuminuria are currently drawing a great 
deal of attention due to the the fact that albumin excretion is a risk factor 
for kidney failure [78,79] , stroke [80,81] , and cardiovascular and all-cause 
mortality [80,82-89], particularly for persons with diabetes and hypertension 
[86-89]
 . Microalbuminuria is not only an adverse factor for the progression 
of diabetic renal disease, but is also predictive of cardiovascular events in 
nondiabetic population[90]. 
PATHOPHYSIOLOGY 
Albumin leakage into the urine is a reflection of widespread vascular 
damage[91]. Endothelial function and chronic inflammation have been 
suggested as possible candidates to explain the association between 
microalbuminuria and CVD [92,93]. Low-grade inflammation can be both a 
cause and a consequence of endothelial dysfunction, and  use of markers 
of inflammation such as C-reactive protein, IL-6, and TNF-α, indicate 
that low-grade inflammation is associated with the occurrence and the 
progression of microalbuminuria and with an associated increased risk for 
atherosclerotic disease [89,94,95] . Other studies indicate that although 
microalbuminuria, endothelial dysfunction, and low-grade inflammation 
are linked, they all are independently associated with risk for 
cardiovascular death [96,97] . 
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               Some individuals are born with varying degrees of vascular 
function within a physiologic range and, therefore, excrete a variable 
amount of microalbumin [98] . This inherent variability of the vascular 
state as determined by urine microalbumin excretion may be associated 
with susceptibility to subsequent organ damage [99] . Hence 
microalbuminuria is a predictor of not only CVD but also new-onset 
hypertension and diabetes [99] . 
SCREENING 
               The traditional  dipstick test used to measure protein in the urine 
is semiquantitative and insensitive, particularly when detecting albumin 
concentrations <300 mg/d. A variety of antibody-based methods are 
available to measure urinary albumin including RIA, nephelometry, 
immunoturbidimetry, and ELISA. The HPLC method is more sensitive to 
detect microalbuminuria [100] . As there is a continuous relationship 
between the amount of urine albumin excretion and cardiovascular 
events, more sensitive measures may assist in the earlier identification of 
patients who are at risk. 
              An albumin-to-creatinine ratio that uses an overnight or first-
morning void urine sample or measurement of albumin excretion per unit 
of time should be used for screening. For an untimed sample, the 
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albumin-to-creatinine ratio is preferred but must be corrected for the 
gender difference in creatinine production between men and women  [77]. 
In addition, creatinine excretion in the urine depends on age and race 
[101,102]
 . Studies have shown first morning void may be able to replace  
24-h urine collection, preferably urinary albumin concentration (UAC) in 
the initial screening of microalbuminuria. [103] 
MANAGEMENT[104] 
The recommendations for management of patients with microalbuminuria 
include  
 Renoprotection with ACE inhibitors or angiotensin receptor  
          blockers for patients with diabetes 
 BP control 
    <140/90 mmHg for the general population 
    <130/80 mmHg for patients with diabetes 
 Glycemic control: hemoglobin A1c <7%  
 Consider screening in patients with diabetes 
 LDL cholesterol control for diabetes in the general population 
    <100 mg/dl (<2.6 mmol/L) for patients with or without      
                diabetes   
    <70 mg/dl (<1.8 mmol/L) for patients with CVD 
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 Correct disturbances in triglyceride, HDL, and non-HDL 
cholesterol levels 
 Smoking cessation 
 Dietary limitation of salt (<3 g/d) and saturated fat 
 Regular exercise and weight control 
 Antiplatelet therapy 
Screening   for    Microalbuminuria    can    help  clinicians   estimate   a  
patient's     CVD     risk     prompt     the     early     introduction     of    a  
multifactorial intervention strategy that aim to improve the overall CVD  
risk factor profile as well as prevent further loss of renal function. 
 
HIV AND MICROALBUMINURIA 
 
The prevalence of microalbuminuria is found to be multi  fold   higher  in  
HIV infected individuals   compared   to  general  population   in   various  
Studies. Many   significant   predictors  including  Female  gender,   BMI,  
Clinical Stage,   CD4   count,  Duration  of  HIV  have  been  observed  to  
predict  microalbuminuria.  The  aim  of this study is to conduct a  similar  
study in our population and to analyse the effect of ART on 
microalbuminuria. 
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MATERIALS AND METHODS 
 
STUDY POPULATION 
       A total of 187 HIV infected patients who attended ART clinic as  
out-patients and admitted in the wards of Institute of Internal Medicine, 
Rajiv Gandhi Government General Hospital, Chennai as in-patients were 
screened. 100 patients were selected who fit into the study based on 
inclusion and exclusion criteria. Written consent was obtained from them 
in the prescribed format after clearly explaining to them the purpose and 
methodology of the study. They were subjected to a routine clinical 
examination and basic laboratory investigations. Urine microalbumin was 
estimated from their early morning urine samples. 50 people who 
satisfied the inclusion and exclusion criteria were selected as control 
population and their urine microalbumin was estimated. 
 
STUDY DURATION 
      The study was conducted from a period from April 2011 to November 
2011. 
 
STUDY DESIGN 
      This is a cross-sectional study to evaluate the prevalence of 
microalbuminuria among HIV infected individuals and to analyse its 
association with Duration of HIV infection, CD4 count, Serum 
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Creatinine, Blood pressure, Glomerular Filtration Rate and cART intake 
independently. 
 
Ethical Committee Approval         :  Obtained   
Informed Consent                          :  Obtained  
Conflict of Interest                         :  There was no conflict of interest 
Financial Support                          :   Nil 
 
METHODS 
History 
       A detailed history was taken from all patients which includes mode 
of detection, symptoms at the time of initial presentation, duration of 
HIV, ART intake, present complaints if any, symptoms of burning 
micturition, antibiotic intake, history of Tuberculosis and treatment for 
the same, smoking and intravenous drug-abuse habits, and knowledge of 
hypertension, diabetes, and cancer and hepatitis B and C status. Those 
who satisfied the inclusion and exclusion criteria were taken into the 
study group. 
 
Examination 
       A detailed general examination and systemic examination was 
performed on all the patients. Blood pressure was measured using 
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sphygmomanometer twice 2 minutes apart using an appropriate cuff after 
the patient had rested in a sitting position for 5 minutes in a quiet room. 
The average of these measurements in duplicate was used for statistical 
analysis of systolic blood pressure (SBP) and diastolic blood pressure 
(DBP). Height and weight were measured to estimate the body mass 
index (BMI) in kg/m2. The detailed general examination was intended to 
specifically look for the presence of pallor, lymphadenopathy, pedal 
edema, stigmata of Tuberculosis,    angular cheilitis, oral ulcerations, 
ulcerative stomatitis, gingivitis or periodontitis, oral candidiasis, oral 
hairy leukoplakia, Herpes zoster, Papular pruritic eruptions, Seborrhoeic  
dermatitis,  Fungal  nail  infections,  Genital  ulcers and Kaposi sarcoma. 
A thorough Cardiovascular, Respiratory, Per abdomen and Central 
Nervous system examination including fundus was performed.  Based on 
clinical examination the disease was staged according to WHO clinical 
staging of HIV disease in adults and adolescents. 
 
Laboratory Investigations 
         A Complete haemogram, Renal function tests, Liver function tests,  
Urine routine analysis including albumin, sugar and deposits, ECG in all 
leads and Chest X ray were performed. The CD4 count, HbsAg and Anti 
HCV status were recorded from the existing database. An Ultrasonogram 
abdomen was done to assess the renal size and echoes. A quantitative 
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determination of microalbumin in urine was done by turbidimetric 
immunoassay in patients who had nil, trace or 1+ albuminuria by dipstick 
assay in a early morning spot urine sample. Those who had 
microalbuminuria by spot urine albumin concentration were confirmed by 
24 hour urine albumin estimation. Those who were found to have 
macroalbuminuria were excluded from the study. 
         Creatinine clearance was calculated by Cockcroft-Gault formula 
using age, sex, body weight and serum creatinine values. Estimated 
Glomerular filtration rate was calculated by MDRD (Modification of Diet 
in Renal Disease) formula using age, race, sex and serum creatinine 
values. 
 
Control Population 
         Healthy control population was selected based on inclusion and 
exclusion criteria . A brief history including a history of Diabetes 
mellitus, Systemic hypertension or any other co-morbid illnesses were 
elicited. Clinical examination was done including the measurement of 
height, weight and blood pressure as described above for cases. Basic 
blood investigations including Complete haemogram, Renal function 
tests, Liver function tests and urine routine analysis were performed. 
Quantitative determination of urine microalbumin was done in early 
morning spot urine samples of those who had nil, trace or 1+ albumin by 
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dipstick assay. Creatinine clearance and estimated GFR were calculated 
as described above.  
 
Interpretation of Results 
         Reference curve was generated by successive 1:2 dilutions of the 
microalbumin calibrator in saline and the reference range established in 
our laboratory was 0-25 mg/L. A concentration above 25mg/L was 
considered as microalbuminuria. 
 
INCLUSION CRITERIA 
        Patients who are recently diagnosed or are known HIV positive   
individuals   either  on  Anti-Retroviral  therapy  or  on pre-ART 
treatment attending ART clinic as out-patients or admitted as in-patients 
in the wards of Institute of Internal Medicine, Rajiv Gandhi Government 
General Hospital. 
 
EXCLUSION CRITERIA 
1. Age above 65 years 
2. Diabetes mellitus 
3. Systemic Hypertension 
4. Documented Chronic kidney disease 
5. Intake of nephrotoxic drugs 
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6. Febrile illness including urinary tract infection 
7. Hepatitis B co-infection 
8. Hepatitis C co-infection 
 
STATISTICAL ANALYSIS 
      Statistical    analysis     was    carried    out    for    100   patients   after  
categorizing each variable – Age,  Sex, Duration of HIV, ART intake, 
Clinical stage, Systolic blood pressure, Diastolic blood pressure ,  Serum  
creatinine ,  Creatinine  clearance,  eGFR  and Microalbuminuria were 
analyzed. Data were analysed using Statistical package- SPSS software 
version 11.5. The significance of difference between the proportions was 
indicated by the chi-square (x2) statistic. The significance of difference in 
mean between the groups was calculated   by   student   t-test.   Variables   
were  considered  to be significant if (P<0.05). Intervariate analysis was 
done by using Pearson’s r- value correlation. 
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OBSERVATION AND RESULTS 
 
 A total of 100 seropositive patients were included in the study and 
50 age and sex matched people constituted the control population. 
 Out of the 100 seropositve individuals 50 were males and 50 were 
females. 
 50 patients were in the Pre-ART group and 50 belonged to the 
ART group. 
 The mean age of control population was 36.14 + 7.36 years and 
that of cases was 35.99 + 8 years. 
 The mean BMI of control population was 22.95 + 3.90 and that of 
cases was 22.30 + 4.47 kg/m2 
 Microalbuminuria was present in 2 out of 50 controls and 24 out of 
100 cases. 
 The mean Urine microalbumin level in seropositive cases was 
38.07 + 48.78 compared to that of controls who had a mean of 
14.28 + 8.35mg/l 
 The mean age of Pre ART group was 34.48 + 7.68 years and that 
of ART group was 37.50 + 8.12 years. 
 The mean BMI of Pre ART group was 23.70 + 4.81 and that of 
ART group was 20.91 + 3.64 kg/m2 which is a statistically 
significant reduction.   
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  Microalbuminuria was present in 17 out of 50 patients belonging 
to the Pre ART group and 7 out of 50 patients belonging to the 
ART group. 
 There was statistically significant decrease in Urine microalbumin 
levels in patients belonging to ART group (Mean of 28.41 + 
36.31mg/l) compared to Pre ART group (Mean of 47.74 + 
57.44mg/l). 
 Of the 100 patients 69 belonged to Stage I, 13 belonged to Stage II, 
13 belonged to Stage III and 5 belonged to Stage IV. 
 There was statistically significant difference in the means of  
Systolic blood pressure, Duration of HIV, CD4 count, eGFR 
calculated by Cockroft Gault and MDRD formulae  between 
patients who did not have microalbuminuria and those who had 
microalbuminuria. 
 No statistical significance was found with Age, BMI, Stage, 
Diastolic blood pressure and Duration of ART with 
microalbuminuria. 
 Significant negative correlation was observed between CD4 count, 
eGFR calculated by Cockroft Gault and MDRD formulae and 
Urine microalbumin level. 
 Significant positive correlation was observed between Systolic 
blood pressure and Urine microalbumin level. 
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 No significant correlation was observed between Age, BMI, 
Duration of HIV ,Diastolic blood pressure and Urine microalbumin 
levels.  
POPULATION CHARACTERISTICS  
AGE DISTRIBUTION 
 
AGE DISTRIBUTION OF CONTROL POPULATION
2%
16%
60%
20%
0%
2%
<20
21-30
31-40
41-50
51-60
>61
 
 
AGE DISTRIBUTION OF CASES
1%
22%
52%
22%
2%
1%
<20
21-30
31-40
41-50
51-60
>61
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SEX DISTRIBUTION 
 
 CONTROL CASES 
MALE 25 50 
FEMALE 25 50 
TOTAL 50 100 
 
SEX DISTRIBUTION OF CONTROL POPULATION
50%50%
MALE
FEMALE
 
 
SEX DISTRIBUTION OF CASES
50%50%
MALE
FEMALE
 
 45 
AGE AND SEX DISTRIBUTION AMONG CASES 
 
 
AGE DISTRIBUTION
0
5
10
15
20
25
30
AGE
NU
M
BE
R
PRE ART
ART
PRE ART 0 15 27 7 0 1
ART 1 7 25 15 2 0
<20 21-30 31-40 41-50 51-60 >60
 
 
 
 
SEX DISTRIBUTION
0
5
10
15
20
25
30
NU
M
BE
R
MALE
FEMALE
MALE 22 28
FEMALE 28 22
PRE ART ART
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BODY MASS INDEX 
 
BODY MASS INDEX
0
5
10
15
20
25
30
35
BMI
NU
M
BE
R
Pre ART
ART
Pre ART 8 22 16 4
ART 13 30 7 0
<18.5 18.5-25 25-30 >30
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ART REGIMEN 
 
 
ART REGIMEN
ZLN
42%
ZFN
6%
SLE
12%
SFE
6%
SLN
8%
SFN
18%
ZLE
8%
 
 
Z    -    Zidovudine 
L    -    Lamivudine 
N    -   Nevirapine 
F     -   Emtricitabine 
E     -   Efavirenz 
S     -   Stavudine 
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STATISTICAL ANALYSIS 
 
COMPARISON OF CASES AND CONTROL POPULATION 
 
 
Cases Controls  
Mean Standard 
deviation 
Mean Standard 
deviation 
 
P value 
Age 35.99 8.00 36.14 7.36 0.912 
BMI 22.30 4.47 22.95 3.90 0.389 
Systolic BP 118.30 7.85 117.28 6.07 0.422 
Diastolic BP 79.70 4.41 78.44 4.20 0.096 
eGFR CG 102.30 33.37 103.92 24.04 0.761 
eGFR MDRD 114.04 27.87 111.68 28.15 0.627 
Microalbumin 38.07 48.78 14.28 8.35 0.001* 
 
 
There is statistically significant difference in urine microalbumin level 
between control population and cases. There is no significant difference 
in Age, BMI, Systolic blood pressure, Diastolic blood pressure and eGFR 
calculated by Cockroft Gault and MDRD formulae between cases and 
control population. 
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MICROALBUMINURIA AMONG CASES AND CONTROLS 
 
 
  Cases Controls 
Present 24 2 Microalbuminuria 
Absent 76 48 
 
 
Microalbuminuria is present in 24% of cases compared to 4% of controls 
with a P value by ChiSquare test of 0.002 which is statistically 
significant. 
 
 
MICROALBUMINURIA
0
10
20
30
40
50
60
70
80
NU
M
BE
R
ABSENT
PRESENT
ABSENT 48 76
PRESENT 2 24
CONTROLS CASES
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MICROALBUMINURIA AND SEX 
 
 Urine Microalbumin 
 Mean Standard Deviation 
Male 37.15 48.46 
Female 39.01 49.57 
 
The P value for sex is 0.850 which is not statistically significant. 
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COMPARISON BETWEEN PRE-ART AND ART GROUPS 
 
Pre ART ART  
Mean Standard 
deviation 
Mean Standard 
deviation 
 
P value 
Age 34.48 7.68 37.50 8.12 0.059 
BMI 23.70 4.81 20.91 3.64 0.001* 
Systolic BP 118.20 8.50 118.40 7.22 0.899 
Diastolic BP 79.64 4.79 79.76 4.05 0.893 
HIV duration 32.08 36.06 42.76 37.39 0.149 
CD4 count 431.94 214.64 371.70 270.76 0.221 
eGFR CG 107.77 35.56 96.84 30.47 0.102 
eGFR MDRD 114.20 28.76 113.88 27.25 0.995 
Microalbumin 47.74 57.44 28.41 36.31 0.047* 
 
 
There is statistically significant difference in BMI and Urine 
microalbumin level between Pre-ART and ART groups. No significant 
difference is observed in Age, Systolic blood pressure, Diastolic blood 
pressure, Duration of HIV, CD4 count, eGFR calculated using Cockroft-
Gault and MDRD formulae between the two groups. 
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MICROALBUMINURIA AMONG PRE-ART AND ART GROUPS 
 
 
  Pre ART ART 
Present 17 7 Microalbuminuria 
Absent 33 43 
 
 
Microalbuminuria is present in 34% of Pre ART group compared to 14% 
in ART group with a P value by ChiSquare test of 0.041 which is 
statistically significant. 
 
MICROALBUMINURIA IN PRE-ART AND ART
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MICROALBUMINURIA AND ART REGIMEN 
 
 
 
 
Microalbuminuria Urine microalbumin Regimen Number 
Present Absent Mean Standard 
deviation 
SLE 6 0 6 17.48 5.27 
SFE 3 0 3 9.56 1.22 
SLN 4 1 3 52.72 84.64 
SFN 9 1 8 21.04 19.07 
ZLE 4 0 4 14.55 3.78 
ZLN 21 5 16 37.36 40.20 
ZFN 3 0 3 14.70 4.68 
 
 
P value by ANOVA is 0.462 and that by Chi-Square test is 0.577 which is 
statistically insignificant. 
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COMPARISON OF PATIENTS WITH AND WITHOUT 
MICROALBUMINURIA 
 
Microalbuminuria  
negative 
Microalbuminuria 
positive 
 
Mean Standard 
deviation 
Mean Standard 
deviation 
 
P value 
Age 35.75 7.625 36.75 9.26 0.596 
BMI 22.52 4.57 21.62 4.16 0.390 
Systolic BP 116.55 7.50 123.83 6.32 0.000* 
Diastolic BP 79.39 4.52 80.67 3.98 0.220 
Duration of 
HIV  
32.03 30.72 54.50 48.94 0.009* 
CD4 count 453.46 243.19 238.29 169.42 0.000* 
eGFR CG 106.06 32.74 90.41 33.24 0.045* 
eGFR 
MDRD 
117.53 26.37 103.00 30.15 0.025* 
Duration of 
ART  
25.88 22.47 9.71 7.95 0.067 
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There is statistically significant difference in Systolic blood pressure, 
Duration of HIV, CD4 count, eGFR calculated by Cockroft Gault and 
MDRD formulae between the two groups. No significant difference is 
observed in Age, BMI, Diastolic blood pressure and Duration of ART 
intake between the two groups. 
 
MICROALBUMINURIA AND STAGE 
 
Stage I II III IV 
Microalbuminuria -ve 54 10 9 3 
Microalbuminuria +ve 15 3 4 2 
 
P value by Chi square test is 0.746 which is statistically insignificant. 
MICROALBUMINURIA AND STAGE
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CORRELATION 
 
Urine Microalbumin  
Correlation coefficient P value 
Age 0.102 0.312 
BMI -0.179 0.075 
HIV duration 0.158 0.116 
CD4 count -0.506 0.000* 
Systolic BP 0.338 0.001* 
Diastolic BP 0.085 0.403 
eGFR CG -0.296 0.003* 
eGFR MDRD -0.290 0.003* 
ART duration -0.274 0.054 
 
 
There is significant negative correlation between Urine microalbumin 
level and CD4 count, eGFR calculated by Cockroft Gault and MDRD 
formulae. There is also a significant positive correlation between Systolic 
blood pressure and Urine microalbumin. No significant correlation is 
observed between Urine microalbumin and Age, BMI, Duration of HIV, 
Diastolic blood pressure and Duration of ART. 
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BINARY LOGISTIC REGRESSION MODEL 
 
Dependent variable        :  Microalbuminuria 
Independent variables :  Age, Sex, BMI, Systolic blood pressure, 
Diastolic blood pressure, Duration of HIV, Clinical Stage, CD4 count, 
ART intake, Duration of ART, eGFR calculated by Cockroft Gault and 
MDRD formulae. 
 
 P value Odds Ratio 
Age 0.332 0.928 
Sex 0.317 0.333 
BMI 0.848 0.950 
Systolic BP 0.002* 1.557 
Diastolic BP 0.061 0.663 
Duration of HIV 0.008* 1.050 
CD4 count 0.003* 0.985 
Stage 0.156 0.419 
ART intake 0.005* 96.823 
Duration of ART 0.100 0.945 
eGFRCG 0.607 0.979 
eGFRMDRD 0.978 1.001 
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From the above table it is evident that Systolic blood pressure, Duration 
of HIV, CD4 count and ART intake are independent predictors of 
microalbuminuria. 
 
 
 
 59 
 DISCUSSION 
 
PREVALENCE OF MICROALBUMINURIA 
 
           The association between HIV infection and microalbuminuria 
based on a single urine sample has previously been observed in selected 
study populations in the pre-cART era, with a prevalence ranging from 19 
to 34% [105-107]. In our study the prevalence was observed to be 24% 
though it was inclusive of population who were on ART as well. 
          There are many other systemic conditions causing 
microalbuminuria which can interfere with the prevalence. To minimize 
such overestimation, patients with known diabetes, hypertension or 
macroalbuminuria were not included in the HIV cohort or in the control 
group as in the study by Morten Baekken et al.[108] 
           The importance of taking repeated measurements has been 
emphasized by Romundstad et al[83], as albumin excretion may vary 
substantially and single-sample measurements lead to an overestimation 
of  the true prevalence of microalbuminuria. This was not done in our 
study as it is a cross-sectional study and follow up was not attempted. 
            
MICROALBUMINURIA AND SEX 
                 Sex predilection has been noticed in studies predicting 
microalbuminuria[109]. Szczech et al[110] has observed female gender as a 
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significant predictor of microalbuminuria. No such sex predilection was 
observed in our study 
 
MICROALBUMINURIA AND BODY MASS INDEX 
                 Body mass index has been observed as a favourable predictor 
of microalbuminuria [109]. But in contrast our study did not demonstrate 
any association between body mass index and microalbuminuria.  
 
MICROALBUMINURIA AND BLOOD PRESSURE 
               Blood pressure has been demonstrated as a major determinant of 
albumin excretion in other populations[111,112] and in an HIV-infected 
cohort[108,110]. In our study systolic blood pressure was observed to be 
associated with microalbuminuria. But no association was found between 
diastolic blood pressure and microalbuminuria.  
            
MICROALBUMINURIA AND DURATION OF HIV 
              Serum beta 2-microglobulin, an inflammatory marker of HIV 
Immunoactivity[113] , emerged as an independent predictor for urinary 
albumin excretion. This novel finding may suggest that other 
pathophysiological mechanisms beyond the haemodynamic effect may be 
linked to microalbuminuria in the HIV-infected state. This is further 
supported by the observation that subjects with microalbuminuria had 
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longer durations of HIV infection than those without 
microalbuminuria[108]. The same inference was observed in our study. 
            
MICROALBUMINURIA AND STAGE 
              Prior  studies  demonstrated  associations  between  the  presence  
of microalbuminuria and ‘stage’ of HIV-infection [106,109]. But in contrast 
to this our study showed no association between clinical stage of the 
disease and microalbuminuria.   
 
MICROALBUMINURIA AND CD4 COUNT 
                Studies have found that HIV RNA level, CD4 lymphocyte 
count, and African–American race were important determinants of overt 
proteinuria [114] and  were associated with higher ACR[110] . Our study too 
showed significant association between CD4 count and 
microalbuminuria. Measurement of HIV RNA level was not undertaken 
in our study.  
 
MICROALBUMINURIA AND ART 
             No   association  was  observed  between  the  use  of   cART   
and Microalbuminuria in results  by Szczech et al[110] and Morten 
Baekken et al.[108]. Nor were there significant differences between the 
duration of cART and microalbuminuria[108]. In our study the 
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microalbuminuria was significantly decreasesd in HIV cohort on cART 
when compared to those not on ART though no association was found 
between duration of cART and microalbuminuria. 
 
MICROALBUMINURIA AND DRUGS 
               A relationship between microalbuminuria and current use of 
NNRTI   was    noted    but    was    not     as     strong     as     the     
association  of  microalbuminuria with other measures[110]. While certain 
antiretroviral medications have been associated with acute renal failure 
and nephrolithiasis [115-118], glomerular damage has not previously been 
reported with those medications and they were not apparently associated 
with microalbuminuria in this study. Tenofovir use was very low at the 
time of this study and indinavir use was not associated with 
microalbuminuria. 
                Our study did not demonstrate any significant association of 
microalbuminuria with ART regimen. However none of our patients were 
on Tenofovir or any of the protease inhibitors.  
 
MICROALBUMINURIA AND RENAL FUNCTION            
              Microalbuminuria was observed to be linked to renal function in 
the study by Morten Baekken et al[108]. In contrast, Szczech et al found no 
difference in serum creatinine or GFR in microalbuminuric compared to 
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normoalbuminuric HIV-infected individuals [110]. On the other hand, in a 
selected South African HIV cohort where persistent microalbuminuric 
patients underwent renal biopsy, six out of seven (86%) patients had 
HIVAN. Microalbuminuria was found to constitute 24% of all patients 
with HIVAN and hence should be considered an early indicator of renal 
disease. Interestingly however, these patients had normal renal 
function[14].  
              In our study eGFR was found to be significantly reduced in 
patients with microalbuminuria though multivariable analysis did not 
show significant association. A variety of renal diseases may occur and 
constitute an increasingly frequent complication during the course of HIV 
infection[119] , hence the presence of microalbuminuria cannot be 
neglected. 
              Post-Mortem studies in New York have shown nearly one-third 
of 89 kidney tissue donors having chronic kidney disease, and evidence 
of some renal pathology was found in 75. The most common diagnoses 
were arterionephrosclerosis, HIV-associated nephropathy and 
glomerulonephritis. Other diagnoses included pyelonephritis, interstitial 
nephritis, diabetic nephropathy, fungal infection and amyloidosis. Over 
one-third of the cases would have been predicted using current diagnostic 
criteria for chronic kidney disease. Based on semi-quantitative analysis of 
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stored specimens, pre-mortem microalbuminuria testing could have 
identified an additional 12 cases[120].  
                 Also, as studies have shown high prevalence of renal 
dysfunction in patients yet to be started on ART[109], screening of patients 
for microalbuminuria becomes much more vital for early detection of 
HIV induced renal dysfunction that too when Tenofovir is being 
recommended as a first line ART which is nephrotoxic. 
                  Studies have demonstrated the association of 
microalbuminuria with all cause mortality in HIV and also graded 
relationship between the degree of microalbuminuria and risk of 
mortality[121].  Also it is the harbinger of future risk of Cardiovascular and 
kidney disease. Given the analogous case scenario of decrement in 
microalbuminuria with agents that disrupt the Renin Angiotensin axis, 
similar therapeutic use in HIV is plausible.  
                      Hence the present study recommends routine screening of 
all HIV infected individuals for microalbuminuria especially those with 
increased duration of HIV infection and low CD4 counts. A follow up of 
patients is also suggested to detect persistent microalbuminuria. Further 
studies can be planned to explore the plausibility of renal biopsy in 
patients with persistent microalbuminuria and early initiation of ART and 
exploring modalities to retard the progression of renal dysfunction.   
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LIMITATIONS OF THE STUDY 
 
1. The sample size is small consisting of 50 controls and 100 cases. 
2. The study was conducted in Rajiv Gandhi Government General 
Hospital, Chennai which is not a representative population of the 
whole state or country. 
3. This is a cross-sectional study and hence follow up study was not 
attempted. 
4. Renal biopsy was not performed in any of the patients due to 
ethical reasons. 
5. Though most of the patients were found to be on Cotrimoxazole 
prophylaxis which causes an increase in serum creatinine values, 
they were included in the study. 
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CONCLUSION 
 
The following conclusions could be arrived based on this study. 
 The prevalence of microalbuminuria is significantly higher in HIV 
cohorts compared to control population.  
 Duration of HIV infection, CD4 count and Systolic blood pressure 
are significant predictors of microalbuminuria. 
 Microalbuminuria can be an indicator of renal dysfunction in HIV 
infected individuals. 
 There is no significant predictive value for Age, Sex, Body mass 
index, Clinical stage and Diastolic blood pressure in predicting 
microalbuminuria. 
 There is significant decrease in the prevalence of microalbuminuria 
in patients on ART compared to those not started on ART. 
 There is no significant association between duration of ART or 
individual ART regimen with microalbuminuria. 
 
                    This study observes the need for routine screening of 
microalbuminuria, early ART initiation and plan future studies on renal 
biopsy for patients with persistent microalbuminuria and therapeutic trials 
to retard the progression of renal dysfunction.  
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PROFORMA 
 
 
 
Name:                                                       Age:                   Sex: 
Address: 
Unit/Ward: 
 
PRESENT HISTORY 
Initial presentation 
Duration of HIV 
Duration of ART intake 
Fever 
Burning Micturition 
 
PAST & PERSONAL H/O 
Jaundice 
Alcoholism 
Blood Transfusion 
Premarital/Extramarital contact 
Tattooing/IV drug abuse 
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CLINICAL EXAMINATION 
 
Anaemia 
Jaundice 
Pedal Oedema 
Stigmata of Tuberculosis 
Lymphadenopathy 
Clubbing 
Weight 
Height 
Body Mass Index 
External markers of HIV infection 
 
 
VITALS 
 
Pulse rate 
Blood Pressure 
Respiratory rate 
Temperature 
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SYSTEMIC EXAMINATION 
Cardiovascular System 
Respiratory system 
Abdomen 
Central Nervous System 
 
 INVESTIGATIONS: 
 
URINE ANALYSIS 
Albumin  
Sugar 
Deposits 
Urine Microalbumin concentration 
 
COMPLETE HEMOGRAM 
Hb (g/dL) 
TC (cells/cmm) 
DC 
RBC(millions/cmm) 
Platelet(Lakhs/cmm) 
PCV 
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RENAL FUNCTION TESTS 
Blood Sugar(mg/dL) 
Blood Urea(mg/dL) 
S. Creatinine(mg/dL) 
 
 
ECG in all leads  
Chest X ray PA view                                                                                                               
USG   Abdomen 
Sputum smear for Acid fast bacilli 
HbsAg 
Anti HCV 
CD4 count 
eGFR ( Calculated using Cockroft Gault and MDRD formulae) 
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PATIENT CONSENT FORM 
 
Study detail: 
“PREVALENCE AND PREDICTORS OF MICROALBUMINURIA IN HIV 
INFECTED INDIVIDUALS” 
Study centre  :             Rajiv Gandhi Government General Hospital, Chennai. 
 
Patients Name  : 
Patients Age  : 
Identification Number        : 
   Patient may check (     ) these boxes 
I  confirm that I have understood the purpose of procedure for the above study. I have the opportunity 
to ask question and all my questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical 
committee and the regulatory authorities will not need my permission to look at my health records, 
both in respect of current study and any further research that may be conducted in relation to it, even if 
I withdraw from the study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from any 
deterioration in my health or well being or any unexpected or unusual symptoms. 
I hereby consent to participate in  this study. 
I hereby  give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical, radiological tests. 
Signature/thumb impression:    
Patients Name and Address:                   Place   Date 
 
Signature of investigator :    
Study investigator’s Name :                               Place   Date      
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1 38 F 55 148 25.1 114 82 12 315 1 0.8 82.79 85 A 22.1
2 33 F 48 154 20.2 116 80 96 581 4 0.7 86.62 102 A 10.7
3 32 F 57 152 24.7 112 80 0 475 1 0.7 103.8 103 A 12.4
4 33 F 65 154 27.4 110 74 60 466 1 0.6 136.8 122 A 11.8
5 31 F 70 154 29.5 106 70 72 579 1 0.7 128.7 104 A 17.1
6 30 F 56 152 24.2 100 76 0 479 1 0.8 90.9 90 A 15.3
7 28 F 54 155 22.5 110 72 0 457 1 0.7 102 106 A 12.2
8 35 F 45 158 18 108 82 7 441 1 0.8 69.72 87 A 10.9
9 32 F 52 158 20.8 114 76 3 369 1 0.7 94.71 103 A 13.4
10 29 F 45 152 19.5 106 74 6 598 1 0.6 98.28 126 A 8.7
11 30 F 80 152 34.6 118 82 28 377 2 0.5 207.7 154 A 15.6
12 28 F 58 158 23.2 106 70 1 319 1 0.7 109.6 106 A 20.2
13 25 F 55 152 23.8 104 70 42 449 1 0.7 106.7 108 A 15.4
14 33 F 60 152 26 110 74 1 403 1 0.5 151.6 151 A 16.2
15 47 F 83 145 39.5 122 84 1 757 1 0.8 113.9 82 A 6.7
16 28 F 61 146 28.6 114 70 30 934 1 0.6 134.4 127 A 4.9
17 40 F 40 150 17.8 114 80 23 760 1 0.6 78.7 118 A 5.8
18 36 F 75 157 30.4 124 80 38 721 1 0.7 131.5 101 A 7.8
19 29 F 55 137 29.3 110 72 19 598 1 0.6 120.1 126 A 11.2
20 38 F 55 147 25.5 122 82 18 484 1 0.7 94.61 100 A 16.8
21 40 M 62 162 23.6 122 84 0 93 1 0.8 107.6 114 A 24.6
22 25 M 41 157 16.6 114 78 5 801 3 0.8 81.85 125 A 9.4
23 40 M 45 159 17.8 120 84 8 371 1 0.8 78.12 114 A 17.2
24 27 M 65 169 22.8 136 88 0 308 4 0.8 127.5 123 A 19.3
25 38 M 75 172 25.4 126 84 6 541 1 0.7 151.7 134 A 14.3
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26 31 M 57 155 23.7 124 80 2 357 3 1 86.26 93 A 10.5
27 29 M 70 165 25.7 110 82 41 510 1 0.6 179.9 169 A 9.7
28 45 M 70 163 26.3 114 80 1 314 1 0.5 184.7 191 A 15.8
29 38 M 60 158 24 120 80 38 524 1 0.7 121.4 134 A 16.6
30 32 M 45 146 21.1 112 80 72 711 1 0.9 75 104 A 8.4
31 23 M 57 171 19.5 116 82 24 399 2 0.9 102.9 111 A 16.3
32 48 M 62 154 26.1 126 84 18 895 1 0.6 132 153 A 5.6
33 36 M 75 172 25.4 122 82 19 541 1 0.7 154.8 136 A 10.7
34 31 F 53 151 23.2 126 84 38 584 1 0.8 85.25 89 P 38.9
35 25 F 35 141 17.6 128 86 24 380 1 0.9 52.49 81 P 82.7
36 36 F 40 153 17.1 126 84 86 180 1 0.8 61.38 86 P 108.5
37 45 F 46 156 18.9 124 80 90 123 3 0.6 85.98 115 P 142.7
38 25 F 30 140 15.3 116 72 3 68 4 2 25.45 42 P 201.4
39 43 F 57 147 26.4 122 80 96 438 1 0.8 81.59 83 P 92.5
40 31 F 45 140 23 112 76 42 281 2 0.6 96.51 124 P 100.4
41 31 F 70 150 31.1 114 76 156 283 1 0.7 128.7 104 P 103.2
42 32 M 65 150 28.9 130 82 39 374 1 0.7 139.3 139 P 95.5
43 65 M 58 155 24.1 136 88 82 81 3 1 43.15 54 P 187.4
44 45 M 45 164 16.7 130 84 124 96 4 0.8 74.21 111 P 177.7
45 43 M 54 160 21.1 118 80 4 85 1 1 72.75 87 P 180.3
46 34 M 57 170 19.7 116 84 1 147 2 0.6 139.9 164 P 138.9
47 31 M 62 168 22 130 82 23 182 1 0.9 104.3 105 P 152.4
48 38 M 65 160 25.4 124 80 39 524 1 0.8 115.1 115 P 42.7
49 36 M 60 150 26.7 134 84 48 610 1 0.7 123.8 136 P 40.8
50 26 M 50 160 19.5 122 82 18 234 1 0.6 131.9 173 P 67.4
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1 35 F 31 142 15.4 108 74 7 7 274 3 0.8 48.03 87 A SLE     21.1
2 34 F 48 161 18.5 122 80 58 36 709 1 0.8 75.08 87 A SFE 8.5
3 29 F 55 155 22.9 118 82 60 22 852 1 0.7 103 105 A SFN 7.2
4 32 F 55 166 20 110 72 67 67 766 2 0.7 100.2 103 A SFN 7.3
5 46 F 45 150 19.6 124 82 2 2 340 3 1 49.93 63 A SFN 15.7
6 28 F 50 157 20.3 110 78 60 40 791 1 0.8 82.63 91 A SFN 6.9
7 57 F 40 147 18.5 128 86 60 12 272 1 0.9 43.54 69 A ZLE     18.9
8 36 F 51 147 23.6 114 72 31 20 381 1 0.8 78.27 86 A ZLN     16.4
9 44 F 58 162 22.1 120 84 48 12 322 2 0.7 93.9 97 A ZLN     16.6
10 35 F 60 164 22.3 106 76 58 58 890 1 0.8 92.96 87 A ZLN     5.9
11 24 F 50 152 21.6 100 72 64 3 285 1 0.5 136.9 161 A ZLN     23.2
12 43 F 64 152 27.7 122 82 3 3 109 3 0.6 122.1 116 A ZLN     24.4
13 34 F 65 150 28.9 112 78 34 6 249 2 0.5 162.7 150 A ZLN     20.7
14 37 F 53 150 23.6 116 82 48 30 274 1 0.7 92.06 100 A ZLN     19.9
15 34 F 66 149 29.7 104 74 31 31 549 1 0.7 118 102 A ZFN 12.3
16 45 F 41 160 16 118 84 64 34 624 1 0.6 76.63 115 A ZFN 11.7
17 21 F 41 150 18.2 104 70 1 1 134 3 0.7 82.28 112 A SLE     21.1
18 42 F 43 145 20.5 118 80 2 2 65 1 0.5 99.49 144 A SFN 24.3
19 36 M 36 154 15.2 120 78 24 24 391 1 0.8 101.1 116 A SLE     18.7
20 30 M 50 160 19.5 120 78 24 24 158 1 0.6 135 168 A SLE     20.9
21 32 M 45 162 17.1 114 80 19 19 662 1 0.8 84.37 119 A SLE     15.4
22 36 M 60 155 25 126 84 60 55 1247 1 0.8 108.3 116 A SLE     7.7
23 46 M 70 161 27 122 84 72 72 852 1 0.6 152.3 154 A SFE 9.3
24 41 M 43 162 16.4 118 78 73 72 355 2 0.7 84.46 132 A SFE 10.9
25 14 M 31 142 15.4 100 74 168 6 300 2 0.9 62.22 117 A SLN     10.1
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26 42 M 75 172 25.4 122 82 60 52 745 1 0.6 170.1 157 A SLN     6.8
27 41 M 37 142 18.3 118 80 72 12 370 2 0.7 72.67 132 A SLN     14.4
28 48 M 55 165 20.2 124 84 60 15 96 1 0.5 140.6 189 A SFN 23.8
29 35 M 60 174 19.8 120 82 62 62 151 1 0.7 131 136 A SFN 21.1
30 48 M 60 169 21 120 78 8 4 323 3 0.8 95.83 110 A SFN 14.7
31 40 M 55 163 20.7 122 80 26 26 403 1 0.7 109.1 133 A ZLE     15.8
32 38 M 50 150 22.2 122 78 1 1 245 4 0.9 78.7 100 A ZLE     13.6
33 56 M 50 169 17.5 128 86 72 44 435 2 0.7 83.33 124 A ZLE     9.9
34 37 M 60 159 23.7 112 82 48 48 239 1 1 85.83 89 A ZLN     17.9
35 31 M 72 162 27.4 116 82 49 49 409 1 0.7 155.7 140 A ZLN     11.6
36 40 M 62 164 23.1 118 84 3 3 93 1 0.8 107.6 114 A ZLN     22.8
37 47 M 40 140 20.4 126 84 2 1 160 1 0.9 57.4 96 A ZLN     14.8
38 37 M 60 162 22.9 124 80 4 4 181 1 1 78.03 80 A ZLN     18.7
39 40 M 55 154 23.2 128 86 8 8 645 3 0.8 95.48 114 A ZLN     8.4
40 34 M 40 165 14.7 116 80 37 36 203 3 0.7 84.12 137 A ZLN     13.8
41 37 M 50 158 20 120 78 31 28 277 1 0.6 119.2 161 A ZLN     14.5
42 31 M 55 166 20 122 82 60 60 642 1 0.8 104.1 120 A ZFN 20.1
43 37 M 50 166 18.1 124 84 2 2 68 2 0.9 79.47 101 A ZLN     24.6
44 34 F 35 148 16 130 80 12 12 71 1 0.8 54.74 87 P SLN     179.6
45 35 F 52 157 21.1 120 82 17 17 159 1 0.7 92.08 101 P ZLN     147.8
46 28 F 55 150 24.4 120 72 80 23 296 1 0.9 80.8 79 P ZLN     114.5
47 30 F 40 154 16.9 122 76 28 4 266 2 0.8 64.93 90 P ZLN     100.9
48 43 M 45 150 20 122 80 6 3 67 3 1 60.62 87 P SFN 68.4
49 48 M 55 160 21.5 130 82 180 2 49 3 0.5 140.6 110 P ZLN     57.8
50 47 M 71 178 22.4 120 80 72 7 141 1 0.8 114.6 110 P ZLN     89.5
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1 38 F    58 154 24.45 122 76 0.7 99.77 100 11.7 A
2 36 F    49 156 20.13 120 82 0.8 75.2 86 18.1 A
3 34 F    61 149 27.47 114 72 0.7 109.04 102 7.3 A
4 42 M    64 161 24.69 120 80 0.6 145.18 157 14.4 A
5 43 F    51 158 20.42 116 70 0.7 83.43 97 0.8 A
6 47 M    58 165 21.3 124 84 1 74.91 85 36.8 P
7 36 M    44 151 19.29 120 78 0.9 70.61 101 13.8 A
8 35 F    63 157 25.55 118 80 0.7 111.56 101 21.1 A
9 28 M    54 167 19.36 122 82 0.6 140 171 3.4 A
10 16 M    47 159 18.59 118 84 0.6 134.9 187 9.8 A
11 27 M    54 168 20.08 124 82 0.8 105.93 123 14.6 A
12 65 M    60 158 24.03 134 84 1.1 56.81 71 49.1 P
13 46 M    68 168 24.09 120 78 0.9 98.64 97 15.6 A
14 35 F    54 157 21.9 122 84 0.8 83.67 87 20.1 A
15 35 F    64 149 28.82 118 78 0.7 113.33 101 9.8 A
16 34 F    71 155 29.55 112 76 0.6 148.08 122 0.9 A
17 31 F    58 149 26.12 108 78 0.7 106.62 104 19.8 A
18 28 F    57 154 24.03 110 72 0.6 125.61 127 12.2 A
19 30 M    55 170 19.03 120 82 0.8 105.03 121 8.3 A
20 38 F    55 157 22.31 114 78 0.8 82.78 85 17.4 A
21 43 M    56 172 18.92 126 80 1 75.44 87 16.1 A
22 30 F    55 148 25.1 114 78 0.8 89.27 90 11.3 A
23 41 M    56 164 20.82 120 80 1 77 88 6.4 A
24 40 M    47 152 20.34 116 78 0.8 89.75 114 22.1 A
25 44 M    54 165 19.83 122 84 0.5 144 192 18.3 A
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26 36 F    46 156 18.9 116 80 0.7 80.68 101 13.4 A
27 27 F    80 155 33.29 118 70 0.8 133.4 91 5.2 A
28 37 F    74 151 32.45 110 72 0.8 112.47 86 7.9 A
29 47 M    54 161 20.83 122 80 1 69.75 85 8.3 A
30 33 F    55 158 22.03 126 70 0.7 99.25 102 12.6 A
31 32 M    47 159 18.59 114 76 0.7 100.71 139 12.3 A
32 36 F    48 153 20.5 116 82 0.8 73.66 86 16.8 A
33 35 M    56 168 19.84 118 80 0.7 116.66 136 11.3 A
34 36 F    54 157 21.9 112 78 0.6 110.5 120 3.8 A
35 46 F    54 152 23.37 122 82 0.5 119.85 141 7.8 A
36 28 M    63 167 22.58 112 80 0.7 140 143 15.6 A
37 36 M    72 169 25.2 120 82 0.8 130 116 23.4 A
38 31 F    45 151 19.73 108 74 0.7 82.72 104 12.5 A
39 32 F    76 148 34.69 110 72 0.8 121.12 88 16.6 A
40 35 M    57 156 23.42 118 78 0.6 138.54 163 4.5 A
41 37 F    36 145 17.12 102 74 0.6 72.95 120 6.2 A
42 34 M    69 166 25.03 110 80 0.7 145.11 137 21.1 A
43 37 F    58 157 23.53 104 82 0.7 100.75 100 12.3 A
44 44 M    70 168 24.8 124 84 1 93.33 86 17.4 A
45 38 M    54 164 20.07 116 82 0.8 95.62 115 11.6 A
46 27 F    56 156 23.01 122 70 0.7 106.72 107 14.4 A
47 39 M    72 168 25.51 118 82 0.9 112.22 100 18.6 A
48 32 M    55 172 18.59 110 78 0.7 117.85 139 19.2 A
49 38 M    56 163 21.07 118 80 0.8 99.16 115 23.2 A
50 32 F    60 154 25.29 124 74 1 76.5 68 19.1 A
